You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm also announced that all of its coronavirus tests would return additional results for Influenzas A and B by the end of September.
The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all rose in August.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
The deal consists of cash, Bionano common stock, and assumption of liabilities. Bionano has also paid off $1.1 million loaned to Lineagen under the CARES act.
The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.
The organization had previously only recommended the use of noninvasive prenatal testing in individuals 35 and older or with other known risk factors.
The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses.
The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.
The Emeryville, California-based instrument maker expects to raise $178.2 million after offering 8.1 million shares at $22 per share.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.